A1 Reactive Astrocytes is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
A1 reactive astrocytes are a neurotoxic subtype of astrocytes that arise in response to neuroinflammation and are implicated in neurodegenerative diseases.[1]
A1 astrocytes were first characterized in 2017 by Liddelow et al. as a distinct reactive phenotype triggered by microglial release of the complement component C1q and IL-1α, and TNF.[1] Unlike healthy astrocytes, A1 astrocytes lose many of their normal supportive functions and instead become toxic to neurons and oligodendrocytes.
A1 astrocytes are characterized by a distinct transcriptional signature:[1]
- C3 (Complement Component 3) - primary marker
- Serping1 - serpin family G member 1
- Emp1 - epithelial membrane protein 1
- Timp1 - TIMP metallopeptidase inhibitor 1
- Cxcl10 - C-X-C motif chemokine ligand 10
- Reduced ability to promote neuronal survival[1]
- Decreased synapse formation and maintenance[1]
- Impaired glutamate uptake (loss of GLT-1/EAAT2)[1]
- Reduced potassium buffering[1]
- Release of neurotoxic factors[1]
- Excessive complement component secretion[1]
- Promotion of synaptic elimination[1]
- Secretion of inflammatory cytokines[1]
A1 astrocytes are found in proximity to amyloid plaques and are thought to contribute to:[2]
- Synaptic loss
- Neuronal death
- Propagation of tau pathology
A1 astrocytes in the substantia nigra may:[3]
- Contribute to dopaminergic neuron loss
- Respond to α-synuclein aggregation
- Promote neuroinflammation
- A1 astrocytes kill motor neurons[4]
- Contribute to disease progression[4]
- A1-like astrocytes observed in demyelinating lesions[5]
- C3 inhibitors - reduce A1 astrocyte formation[2]
- IL-1 receptor antagonists - block A1 induction[2]
- Microglial modulation - prevent initial trigger[2]
The study of A1 Reactive Astrocytes has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Liddelow SA, et al. (2017). Neurotoxic reactive astrocytes are induced by activated microglia. Nature, 541(7638), 481-487. https://www.nature.com/articles/nature21039
- Yun SP, et al. (2018). Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson's disease. Nature Medicine, 24(7), 931-938. https://www.nature.com/articles/s41591-018-0135-0
- Escott C, et al. (2021). A1 astrocytes in neurodegenerative disease. Nature Reviews Neurology, 17(10), 597-612. https://www.nature.com/articles/nrneurol.2021.115
- Papadimitriou D, et al. (2021). Astrocyte toxicity in ALS: mechanisms and therapeutic targets. Nature Reviews Neurology, 17(5), 285-299.
- Ponath G, et al. (2017). Astrocyte phenotypes and their relationship to demyelination. Nature Reviews Neurology, 13(9), 537-548.